Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TA et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):S1–S276. https://doi.org/10.1016/j.kint.2021.05.021

Article  Google Scholar 

Hull RP, Goldsmith DJA (2008) Nephrotic syndrome in adults. BMJ 336(7654):1185–1189. https://doi.org/10.1136/bmj.39576.709711.80

Article  PubMed  PubMed Central  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/nejmoa2024816

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/nejmoa1811744

Article  CAS  PubMed  Google Scholar 

Herrington WG, Staplin N, Wanner C, Green JB, Judge P, Mayne KJ (2023) Empagliflozin in patients with Chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233

Article  PubMed  Google Scholar 

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C et al (2018) SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. https://doi.org/10.1172/jci.insight.98720

Article  PubMed  PubMed Central  Google Scholar 

Kalay Z, Sahin OE, Copur S, Danacı S, Ortiz A, Yau K et al (2023) SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J 16(1):52. https://doi.org/10.1093/CKJ/SFAC189

Article  CAS  PubMed  Google Scholar 

Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Houet FF (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dialysis Transplant. 37(9):1647–1656. https://doi.org/10.1093/ndt/gfab335

Article  CAS  Google Scholar 

Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T et al (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215–224. https://doi.org/10.1016/j.kint.2021.03.033

Article  CAS  PubMed  Google Scholar 

Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2022) Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 37(7):1317–1329. https://doi.org/10.1093/ndt/gfac040

Article  CAS  Google Scholar 

Elkeraie A, Zyada R, Elrggal ME, Elrggal M (2023) Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-023-03508-1

Article  PubMed  Google Scholar 

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737–1749. https://doi.org/10.1056/NEJMoa2102953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ et al (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8(7):582–593. https://doi.org/10.1016/S2213-8587(20)30162-5

Article  CAS  PubMed  Google Scholar 

Boeckhaus J, Gross O (2021) Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, alport syndrome, and fsgs: a case series to better plan a large-scale study. Cells. https://doi.org/10.3390/cells10071815

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Cui J, Fang X, Chen J, Yan W, Shenet Q et al (2022) Efficacy and safety of dapagliflozin in children with inherited Proteinuric kidney disease: a pilot study. Kidney Int Rep 7(3):638–641. https://doi.org/10.1016/j.ekir.2021.12.019

Article  PubMed  Google Scholar 

Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y et al (2018) Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Physiol Renal Physiol 314:412–422. https://doi.org/10.1152/ajprenal.00445.2017.-Focal

Article  CAS  Google Scholar 

Oliva-Damaso N, Mora-Gutiérrez JM, Bomback AS (2021) Glomerular diseases in diabetic patients: implications for diagnosis and management. J Clin Med. https://doi.org/10.3390/jcm10091855

Article  PubMed  PubMed Central  Google Scholar 

Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353–1368. https://doi.org/10.1001/jama.2020.1906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116–2124. https://doi.org/10.1111/dom.14451

Article  CAS  PubMed  Google Scholar 

Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E (2020) Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes 128(8):506–511. https://doi.org/10.1055/a-0664-7583

Article  CAS  PubMed  Google Scholar 

Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET et al (2014) Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 1(1):3–8. https://doi.org/10.1016/j.jcte.2013.12.001

Article  CAS  Google Scholar 

Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61(10):2098–2107. https://doi.org/10.1007/S00125-018-4669-0

Article  CAS  PubMed  Google Scholar 

Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW (2017) Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab 19(1):49–60. https://doi.org/10.1111/dom.12779

Article  CAS  PubMed  Google Scholar 

Bays HE, Weinstein R, Law G, Canovatchel W (2014) Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 22(4):1042–1049. https://doi.org/10.1002/oby.20663

Article  CAS  PubMed  Google Scholar 

Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M (2018) SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol 14(11):1113–1121. https://doi.org/10.1080/17425255.2018.1541348

Article  CAS  PubMed  Google Scholar 

Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK et al (2016) Benefits and harms of sodium-glucose Co-transporter 2 inhibitors in patients with Type 2 diabetes: a systematic review and meta-analysis. PLoS One 11(11):e0166125. https://doi.org/10.1371/journal.pone.0166125

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA et al (2018) Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with Type 2 Diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.007165

Article  PubMed  PubMed Central  Google Scholar